8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 11, 2026·SEC
Material company update
Mar 5, 2026·SEC
Lineage Cell Therapeutics, Inc.(LCTX)Earnings, Financials & Key Ratios
LCTX•AMEX
Price updated Jun 19, 2026
AboutLineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Show more
- Revenue$15M+53.2%
- EBITDA-$21M-1.0%
- Net Income-$64M-241.4%
- EPS (Diluted)-0.28-201.1%
- Gross Margin94.19%-2.4%
- EBITDA Margin-144.82%+34.1%
- Operating Margin-149.62%+33.8%
- Net Margin-436.47%-122.8%
- ROE-105.57%-294.4%
LCTX Key Insights
Lineage Cell Therapeutics, Inc. (LCTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 79.9%
✗Weaknesses
- ✗Profits declining 25.2% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 16 (bottom 16%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 14.9% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LCTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LCTX Price & Volume
Lineage Cell Therapeutics, Inc. (LCTX) stock price & volume — 10-year historical chart
Loading chart...
LCTX Growth Metrics
Lineage Cell Therapeutics, Inc. (LCTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.1%
5 Years79.88%
3 Years-0.33%
TTM54.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-296.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-240.02%
Return on Capital
10 Years-30.73%
5 Years-26.86%
3 Years-23.88%
Last Year-21.73%
LCTX Recent Earnings
Lineage Cell Therapeutics, Inc. (LCTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.03-50.0%
$0.02
Rev
$2M-52.1%
$4M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.00+109.2%
$0.04
Rev
$7M+236.8%
$2M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.13-550.0%
$0.02
Rev
$4M+87.8%
$2M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.01+50.0%
$0.02
Rev
$3M+46.4%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.03vs $0.02-50.0% | $2Mvs $4M-52.1% |
| Q2 2026 | Mar 5, 2026 | $0.00vs $0.04+109.2% | $7Mvs $2M+236.8% |
| Q4 2025 | Nov 6, 2025 | $0.13vs $0.02-550.0% | $4Mvs $2M+87.8% |
| Q3 2025 | Aug 12, 2025 | $0.01vs $0.02+50.0% | $3Mvs $2M+46.4% |
Based on last 12 quarters of dataView full earnings history →
LCTX Peer Comparison
Lineage Cell Therapeutics, Inc. (LCTX) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 OCGN | 419.77M | 1.24 | -5.39 | 8.83% | -16.05% | -1279.88% | ||
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 CELC | 4.28B | 87.76 | -23.22 | -244.61% | 1.94 |
Compare LCTX vs Peers
Lineage Cell Therapeutics, Inc. (LCTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LCTX Income Statement
Lineage Cell Therapeutics, Inc. (LCTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.79M | 1.42M | 1.48M | 773K | 3.9M | 14.7M | 8.95M | 9.5M | 14.56M | 14.78M |
Revenue Growth % | -20.43% | -20.98% | 4.38% | -47.7% | 404.01% | 277.39% | -39.16% | 6.19% | 53.24% | 54.64% |
Cost of Goods Sold | 168K | 302K | 412K | 385K | 1.43M | 728K | 671K | 334K | 845K | 298K |
COGS % of Revenue | 9.38% | 21.33% | 27.88% | 49.81% | 36.6% | 4.95% | 7.5% | 3.52% | 5.81% | - |
Gross Profit | 1.62M▲ 0% | 1.11M▼ 31.4% | 1.07M▼ 4.3% | 388K▼ 63.6% | 2.47M▲ 536.6% | 13.97M▲ 465.8% | 8.27M▼ 40.8% | 9.16M▲ 10.8% | 13.71M▲ 49.6% | 14.48M▲ 0% |
Gross Margin % | 90.63% | 78.67% | 72.12% | 50.19% | 63.4% | 95.05% | 92.5% | 96.48% | 94.19% | 97.98% |
Gross Profit Growth % | -14.26% | -31.4% | -4.31% | -63.6% | 536.6% | 465.79% | -40.79% | 10.77% | 49.6% | - |
Operating Expenses | 42.28M | 42.11M | 39.94M | 26.84M | 51.68M | 36.49M | 33.01M | 30.64M | 35.49M | 52.19M |
OpEx % of Revenue | 2359.38% | 2973.8% | 2702.44% | 3471.54% | 1326.51% | 248.21% | 369% | 322.59% | 243.82% | - |
Selling, General & Admin | 19.92M | 24.73M | 24.03M | 15.57M | 18.21M | 22.51M | 17.3M | 18.17M | 18.46M | 18.69M |
SG&A % of Revenue | 1111.72% | 1746.19% | 1625.91% | 2014.36% | 467.45% | 153.08% | 193.43% | 191.29% | 126.82% | - |
Research & Development | 24.02M | 20.95M | 17.95M | 12.32M | 33.91M | 13.99M | 15.71M | 12.47M | 17.73M | 18.85M |
R&D % of Revenue | 1340.63% | 1479.87% | 1214.34% | 1593.4% | 870.48% | 95.13% | 175.57% | 131.3% | 121.8% | - |
Other Operating Expenses | 1.45M | -1.31M | -2.04M | -1.05M | -445K | 0 | 0 | 0 | -699K | 812K |
Operating Income | -38.9M▲ 0% | -41.8M▼ 7.4% | -38.88M▲ 7.0% | -26.45M▲ 32.0% | -49.21M▼ 86.1% | -22.52M▲ 54.2% | -24.73M▼ 9.8% | -21.48M▲ 13.2% | -21.78M▼ 1.4% | -37.71M▲ 0% |
Operating Margin % | -2170.87% | -2951.62% | -2630.31% | -3421.35% | -1263.12% | -153.17% | -276.5% | -226.11% | -149.62% | -255.14% |
Operating Income Growth % | 34.03% | -7.44% | 6.98% | 31.97% | -86.07% | 54.24% | -9.83% | 13.16% | -1.4% | - |
EBITDA | -35.61M | -38.52M | -35.88M | -24.41M | -48.34M | -21.79M | -24.04M | -20.87M | -21.08M | -36.98M |
EBITDA Margin % | -1986.94% | -2720.48% | -2427.33% | -3157.57% | -1240.71% | -148.22% | -268.76% | -219.7% | -144.82% | -250.25% |
EBITDA Growth % | 34.32% | -8.19% | 6.87% | 31.97% | -98.04% | 54.92% | -10.32% | 13.19% | -1.01% | -78.46% |
D&A (Non-Cash Add-back) | 3.3M | 3.27M | 3M | 2.04M | 873K | 727K | 692K | 609K | 699K | 723K |
EBIT | -40.66M | -40.99M | -38.88M | -26.45M | -49.21M | -22.52M | -24.73M | -21.48M | -21.78M | -48.83M |
Net Interest Income | -692K | 711K | 1.69M | 1.04M | 2K | 829K | 1.63M | 1.72M | 1.69M | 1.25M |
Interest Income | 0 | 0 | 1.69M | 1.04M | 2K | 829K | 1.63M | 1.72M | 1.69M | 1.25M |
Interest Expense | 692K | 10.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 15.61M | -5.33M | 19.64M | 4.52M | 5.94M | -3.29M | 1.45M | 2.9M | -46.87M | -31.59M |
Pretax Income | -23.29M▲ 0% | -47.13M▼ 102.4% | -19.23M▲ 59.2% | -21.92M▼ 14.0% | -43.27M▼ 97.4% | -25.81M▲ 40.3% | -23.28M▲ 9.8% | -18.58M▲ 20.2% | -68.65M▼ 269.4% | -69.29M▲ 0% |
Pretax Margin % | -1299.61% | -3328.39% | -1301.35% | -2836.22% | -1110.63% | -175.56% | -260.28% | -195.62% | -471.61% | -468.86% |
Income Tax | 0 | -346K | -7.41M | -1.24M | 0 | 541K | -1.8M | 0 | -5.11M | -5.28M |
Effective Tax Rate % | 0% | 0.73% | 38.51% | 5.65% | 0% | -2.1% | 7.74% | 0% | 7.45% | 7.62% |
Net Income | -19.98M▲ 0% | -45.99M▼ 130.2% | -11.71M▲ 74.5% | -20.65M▼ 76.4% | -43.02M▼ 108.3% | -26.27M▲ 38.9% | -21.49M▲ 18.2% | -18.61M▲ 13.4% | -63.53M▼ 241.4% | -64.21M▲ 0% |
Net Margin % | -1114.73% | -3247.88% | -792.22% | -2671.28% | -1104.18% | -178.69% | -240.2% | -195.9% | -436.47% | -434.44% |
Net Income Growth % | -159.5% | -130.23% | 74.54% | -76.35% | -108.33% | 38.93% | 18.22% | 13.39% | -241.41% | -296.19% |
Net Income (Continuing) | -23.29M | -46.78M | -11.83M | -20.68M | -43.27M | -26.35M | -21.48M | -18.58M | -63.53M | -64.01M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 1.62M | -1.59M | -1.71M | -1.07M | -1.32M | -1.4M | -1.4M | -1.37M | -1.2M | -1.18M |
EPS (Diluted) | -0.17▲ 0% | -0.36▼ 111.8% | -0.08▲ 77.4% | -0.14▼ 72.2% | -0.26▼ 85.7% | -0.15▲ 42.3% | -0.12▲ 20.0% | -0.09▲ 22.5% | -0.28▼ 201.1% | -0.25▲ 0% |
EPS Growth % | -150% | -111.76% | 77.42% | -72.2% | -85.71% | 42.31% | 20% | 22.5% | -201.08% | -240.02% |
EPS (Basic) | -0.17 | -0.36 | -0.08 | -0.14 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 | - |
Diluted Shares Outstanding | 114.48M | 126.9M | 145.53M | 150.04M | 164.5M | 169.79M | 172.66M | 200.19M | 230.12M | 261.18M |
Basic Shares Outstanding | 114.48M | 126.9M | 145.53M | 150.04M | 164.5M | 169.79M | 172.66M | 200.19M | 230.12M | 245.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LCTX Balance Sheet
Lineage Cell Therapeutics, Inc. (LCTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 42.62M | 36.36M | 57.52M | 44M | 111.55M | 60M | 38.44M | 51M | 59.16M | 56.16M |
Cash & Short-Term Investments | 38.17M | 30.74M | 30.72M | 41.56M | 58.36M | 57.88M | 35.49M | 47.8M | 55.78M | 53.38M |
Cash Only | 36.84M | 23.59M | 9.5M | 32.59M | 55.74M | 11.36M | 35.44M | 45.79M | 40.79M | 35.94M |
Short-Term Investments | 1.34M | 7.15M | 21.22M | 8.98M | 2.62M | 46.52M | 50K | 2.02M | 14.99M | 17.44M |
Accounts Receivable | 3.05M | 3.72M | 24.74M | 4K | 50.84M | 297K | 745K | 638K | 1.56M | 806K |
Days Sales Outstanding | 620.42 | 958.64 | 6.11K | 1.89 | 4.76K | 7.37 | 30.4 | 24.52 | 39.17 | 16.99 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.06M | 0 | 0 | 1.83M | 2.2M | 2.55M | 1.81M | 1.98M |
Total Non-Current Assets | 130.62M | 65.3M | 67.96M | 63.95M | 63M | 63.66M | 62.58M | 62.22M | 53.43M | 53.37M |
Property, Plant & Equipment | 5.53M | 5.83M | 8.18M | 5.63M | 4.87M | 5.67M | 4.77M | 4.39M | 4.7M | 4.62M |
Fixed Asset Turnover | 0.32x | 0.24x | 0.18x | 0.14x | 0.80x | 2.59x | 1.88x | 2.16x | 3.10x | 3.31x |
Goodwill | 0 | 0 | 10.67M | 10.67M | 10.67M | 10.67M | 10.67M | 10.67M | 10.67M | 10.67M |
Intangible Assets | 6.9M | 3.13M | 48.25M | 47.03M | 46.82M | 46.69M | 46.56M | 46.54M | 31.7M | 31.7M |
Long-Term Investments | 117.17M | 33.73M | 100K | 0 | 0 | 581K | 0 | 0 | 0 | 537K |
Other Non-Current Assets | 1.02M | 505K | 764K | 616K | 630K | 627K | 577K | 614K | 558K | 36K |
Total Assets | 173.24M▲ 0% | 101.66M▼ 41.3% | 125.48M▲ 23.4% | 107.95M▼ 14.0% | 174.54M▲ 61.7% | 123.66M▼ 29.2% | 101.02M▼ 18.3% | 113.22M▲ 12.1% | 112.58M▼ 0.6% | 109.53M▲ 0% |
Asset Turnover | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x | 0.12x | 0.09x | 0.08x | 0.13x | 0.15x |
Asset Growth % | 21.51% | -41.32% | 23.43% | -13.97% | 61.69% | -29.15% | -18.31% | 12.08% | -0.56% | -21.42% |
Total Current Liabilities | 6.88M | 6.81M | 6.49M | 7.77M | 47.12M | 18.98M | 17.96M | 13.98M | 11.37M | 8.15M |
Accounts Payable | 938K | 2.36M | 2.43M | 2.61M | 3.54M | 2.39M | 2.05M | 1.17M | 2.34M | 5.57M |
Days Payables Outstanding | 2.04K | 2.85K | 2.15K | 2.48K | 906.87 | 1.2K | 1.12K | 1.28K | 1.01K | 4.27K |
Short-Term Debt | 152K | 70K | 1.22M | 523K | 0 | 0 | 0 | 0 | 853K | 865K |
Deferred Revenue (Current) | 797K | 42K | 45K | 193K | 18.12M | 9.42M | 10.81M | 7.39M | 3.33M | 10.31M |
Other Current Liabilities | 2.5M | 1.65M | 1.25M | 1.97M | 2.54M | 3.83M | 3.12M | 0 | 4.84M | -2.74M |
Current Ratio | 6.20x | 5.34x | 8.86x | 5.66x | 2.37x | 3.16x | 2.14x | 3.65x | 5.20x | 6.89x |
Quick Ratio | 6.20x | 5.34x | 8.86x | 5.66x | 2.37x | 3.16x | 2.14x | 3.65x | 5.20x | 6.89x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -4.26K |
Total Non-Current Liabilities | 2.1M | 2.6M | 7.74M | 5.05M | 36.53M | 32.75M | 21.04M | 22.23M | 57.87M | 48.69M |
Long-Term Debt | 18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 1.15M | 1.96M | 3.94M | 2.54M | 1.97M | 2.94M | 2.07M | 1.36M | 1.57M | 5.76M |
Deferred Tax Liabilities | 0 | 0 | 3.31M | 2.08M | 2.08M | 2.08M | 273K | 273K | 22K | 317K |
Other Non-Current Liabilities | 930K | 644K | 277K | 437K | 30K | 2K | 0 | 6.16M | 56.28M | 34.14M |
Total Liabilities | 8.98M | 9.41M | 14.23M | 12.82M | 83.65M | 51.73M | 39M | 36.21M | 69.24M | 56.84M |
Total Debt | 1.53M | 2.27M | 5.17M | 3.83M | 2.8M | 3.9M | 2.95M | 2.51M | 2.42M | 2.39M |
Net Debt | -35.3M | -21.32M | -4.33M | -28.76M | -52.94M | -7.46M | -32.49M | -43.27M | -38.37M | -33.55M |
Debt / Equity | 0.01x | 0.02x | 0.05x | 0.04x | 0.03x | 0.05x | 0.05x | 0.03x | 0.06x | 0.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.91x |
Interest Coverage | -58.75x | -3.77x | - | - | - | - | - | - | - | - |
Total Equity | 164.26M▲ 0% | 92.25M▼ 43.8% | 111.25M▲ 20.6% | 95.13M▼ 14.5% | 90.9M▼ 4.4% | 71.94M▼ 20.9% | 62.02M▼ 13.8% | 77.01M▲ 24.2% | 43.35M▼ 43.7% | 52.7M▲ 0% |
Equity Growth % | 25.86% | -43.84% | 20.6% | -14.49% | -4.45% | -20.86% | -13.78% | 24.17% | -43.72% | -173.31% |
Book Value per Share | 1.43 | 0.73 | 0.76 | 0.63 | 0.55 | 0.42 | 0.36 | 0.38 | 0.19 | 0.20 |
Total Shareholders' Equity | 162.64M | 93.84M | 112.96M | 96.2M | 92.22M | 73.34M | 63.42M | 78.38M | 44.55M | 53.88M |
Common Stock | 378.49M | 354.27M | 387.06M | 393.94M | 434.53M | 440.28M | 451.34M | 484.72M | 515.47M | 529.66M |
Retained Earnings | -216.3M | -261.86M | -273.42M | -294.08M | -337.1M | -363.37M | -384.86M | -403.46M | -467M | -471.81M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 451K | 1.43M | -681K | -3.67M | -5.21M | -3.57M | -3.07M | -2.88M | -3.92M | -7.94M |
Minority Interest | 1.62M | -1.59M | -1.71M | -1.07M | -1.32M | -1.4M | -1.4M | -1.37M | -1.2M | -1.18M |
LCTX Cash Flow Statement
Lineage Cell Therapeutics, Inc. (LCTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -30.52M | -30.88M | -31.95M | -19.75M | -23.56M | 1.06M | -28.57M | -23.09M | -18.92M | -22.11M |
Operating CF Margin % | -1702.96% | -2180.93% | -2161.5% | -2555.37% | -604.75% | 7.2% | -319.35% | -243.1% | -129.97% | - |
Operating CF Growth % | 27.9% | -1.2% | -3.45% | 38.17% | -19.28% | 104.49% | -2797.45% | 19.16% | 18.07% | -11.69% |
Net Income | -23.29M | -46.78M | -11.83M | -20.68M | -43.27M | -26.35M | -21.49M | -18.61M | -63.53M | -64.21M |
Depreciation & Amortization | 3.3M | 3.27M | 3M | 2.04M | 873K | 727K | 692K | 609K | 699K | 723K |
Stock-Based Compensation | 3.93M | 5.4M | 3.58M | 2.23M | 3.52M | 4.29M | 4.64M | 5.08M | 4.75M | 2.34M |
Deferred Taxes | -17.57M | -346K | -7.41M | -1.24M | -6M | 0 | -1.8M | 0 | -5.28M | -5.28M |
Other Non-Cash Items | 640K | 6.93M | -17.34M | -3.47M | 202K | 3.73M | 195K | -1.4M | 48.55M | 48.57M |
Working Capital Changes | 2.48M | 638K | -1.96M | 1.37M | 21.11M | 18.67M | -10.8M | -8.77M | -4.11M | -4.45M |
Change in Receivables | -172K | 46K | 467K | 287K | -857K | 50.31M | -446K | 106K | -316K | -586K |
Change in Inventory | 1.3M | 122K | 2.88M | -308K | -72K | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.3M | 1.1M | -2.88M | 308K | 21.64M | -18.7M | -2.29M | -1.68M | 2.27M | 394K |
Cash from Investing | -10.22M | 11.82M | 16.96M | 13.04M | 9.74M | -46.16M | 46.45M | -2.31M | -13.46M | -17.69M |
Capital Expenditures | -1.33M | -3.29M | -440K | -64K | -354K | -413K | -674K | -565K | -522K | -192K |
CapEx % of Revenue | 74% | 232.13% | 29.77% | 8.28% | 9.09% | 2.81% | 7.53% | 5.95% | 3.59% | 1.3% |
Acquisitions | -8.9M | 15.11M | 17.33M | 13.06M | 10.09M | 45.75M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 188K | -8K | 65K | 41K | 14K | -45.75M | 0 | 0 | 0 | -288K |
Cash from Financing | 55.39M | 5.77M | 617K | 29.86M | 36.93M | 1.63M | 6.42M | 35.86M | 26.95M | 27.47M |
Debt Issued (Net) | 172K | -349K | -100K | -26K | -20K | -32K | -54K | -54K | -59K | -59K |
Equity Issued (Net) | 58.79M | 4.76M | -110K | 5.1M | 30.81M | 131K | 6.51M | 35.85M | 27.02M | 25.95M |
Dividends Paid | 0 | -34.41M | -182K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -888K | -241K | -110K | -27K | -54K | -17K | -37K | -23K | 0 | 0 |
Other Financing | -3.57M | 35.77M | 1.01M | 24.79M | 6.14M | 1.53M | -37K | 58K | -16K | 1.58M |
Net Change in Cash | 14.75M▲ 0% | -13.29M▼ 190.1% | -14.3M▼ 7.7% | 23.09M▲ 261.4% | 23.09M▲ 0.0% | -44.34M▼ 292.0% | 24.06M▲ 154.3% | 10.36M▼ 56.9% | -5.03M▼ 148.5% | -11.87M▲ 0% |
Free Cash Flow | -31.84M▲ 0% | -34.17M▼ 7.3% | -32.39M▲ 5.2% | -19.82M▲ 38.8% | -23.91M▼ 20.7% | 646K▲ 102.7% | -29.24M▼ 4626.3% | -23.66M▲ 19.1% | -19.44M▲ 17.8% | -22.3M▲ 0% |
FCF Margin % | -1776.95% | -2413.07% | -2191.27% | -2563.65% | -613.83% | 4.39% | -326.89% | -249.05% | -133.56% | -150.91% |
FCF Growth % | 29% | -7.3% | 5.22% | 38.81% | -20.68% | 102.7% | -4626.32% | 19.09% | 17.82% | 1.4% |
FCF per Share | -0.28 | -0.27 | -0.22 | -0.13 | -0.15 | 0.00 | -0.17 | -0.12 | -0.08 | -0.09 |
FCF Conversion (FCF/Net Income) | 1.53x | 0.67x | 2.73x | 0.96x | 0.55x | -0.04x | 1.33x | 1.24x | 0.30x | 0.35x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -41K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LCTX Key Ratios
Lineage Cell Therapeutics, Inc. (LCTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -13.55% | -35.86% | -11.51% | -20.01% | -46.25% | -32.27% | -32.08% | -26.77% | -105.57% | -156.65% |
Return on Invested Capital (ROIC) | -24.18% | -31.36% | -32.79% | -22.89% | -70.76% | -32.98% | -39.46% | -50.92% | -84.39% | -803.82% |
Gross Margin | 90.63% | 78.67% | 72.12% | 50.19% | 63.4% | 95.05% | 92.5% | 96.48% | 94.19% | 97.98% |
Net Margin | -1114.73% | -3247.88% | -792.22% | -2671.28% | -1104.18% | -178.69% | -240.2% | -195.9% | -436.47% | -434.44% |
Debt / Equity | 0.01x | 0.02x | 0.05x | 0.04x | 0.03x | 0.05x | 0.05x | 0.03x | 0.06x | 0.05x |
Interest Coverage | -58.75x | -3.77x | - | - | - | - | - | - | - | - |
FCF Conversion | 1.53x | 0.67x | 2.73x | 0.96x | 0.55x | -0.04x | 1.33x | 1.24x | 0.30x | 0.35x |
Revenue Growth | -20.43% | -20.98% | 4.38% | -47.7% | 404.01% | 277.39% | -39.16% | 6.19% | 53.24% | 54.64% |
Related:LCTX Dividend History·LCTX Revenue History·LCTX Price History·LCTX P/E History·LCTX Financial Ratios·LCTX Institutional Holders
LCTX SEC Filings & Documents
Lineage Cell Therapeutics, Inc. (LCTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
LCTX Frequently Asked Questions
Lineage Cell Therapeutics, Inc. (LCTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lineage Cell Therapeutics, Inc. (LCTX) reported $14.8M in revenue for fiscal year 2025. This represents a 14679% increase from $0.1M in 1996.
Lineage Cell Therapeutics, Inc. (LCTX) grew revenue by 53.2% over the past year. This is strong growth.
Lineage Cell Therapeutics, Inc. (LCTX) reported a net loss of $64.2M for fiscal year 2025.
Dividend & Returns
Lineage Cell Therapeutics, Inc. (LCTX) has a return on equity (ROE) of -105.6%. Negative ROE indicates the company is unprofitable.
Lineage Cell Therapeutics, Inc. (LCTX) had negative free cash flow of $22.3M in fiscal year 2025, likely due to heavy capital investments.